

**Table S1: WalKR mutations in Australian ST239 MRSA**

<b>Mutation</b>	<b>Isolate Region Year</b>	<b>Clade</b>	<b>Vancomycin MIC (<math>\mu\text{g/mL}</math>)<sup>a</sup></b>	<b>MET Interpretation</b>
WalR <sub>A98T</sub>	JKD6001 VIC 2003	2	4	VISA
WalR <sub>T103M</sub>	BPH0503 VIC 2003	2	3	VISA
WalR <sub>K210R</sub>	JKD6005 QLD 2002	1	3	VISA
	JKD6008 NZD 2003	1	4	VISA
WalK <sub>S9F</sub>	BPH0488 VIC 2003	2	3	VISA
WalK <sub>M220I</sub>	BPH2055 VIC 1982	1	3	VISA
WalK <sub>A243T</sub>	BPH0510 NSW 2005	1	3	VISA
WalK <sub>V268F</sub>	JKD6023 VIC 2001	1	1.5	hVISA
WalK <sub>A361V</sub>	BPH2031 VIC 2008	2	2	VSSA
WalK <sub>M426I</sub>	BPH0494 QLD 2005	1	2	hVISA
WalK <sub>A502V</sub>	BPH0499 VIC 2005	2	3	VISA

<sup>a</sup> As determined by Etest

MET, macro-Etest; MIC, minimum inhibitory concentration; VISA, vancomycin-intermediate *S. aureus*; hVISA, heterogeneous VISA; VSSA, vancomycin-susceptible *S. aureus*; VIC, Victoria; QLD, Queensland; NSW, New South Wales; NZD, New Zealand